Drug Trial Radar · NCT05704738
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
532
Actual
Start
Apr 20, 2023
Primary completion
Feb 27, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jan 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent participants.
Conditions
- Atopic Dermatitis
Interventions
RocatinlimabDrug
Subcutaneous (SC) injection
PlaceboDrug
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Achieved vIGA-AD 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24Time frame: Baseline and Week 24
- Number of Participants Who Achieved EASI 75 at Week 24Time frame: Baseline and Week 24
Locations
246 sites in 22 countries. Site status is shown where the registry gives one.
Cahaba Dermatology and Skin Health Center
Birmingham, Alabama
AllerVie Clinical Research- Cullman
Cullman, Alabama
Eclipse Clinical Research
Tucson, Arizona
Arkansas Research Trials, LLC
North Little Rock, Arkansas
Center for Dermatology Clinical Research Inc
Fremont, California
Doc1 Healthcare Systems Incorporated
Fullerton, California
Axon Clinical Research
Inglewood, California
Avance Clinical Trials
Laguna Niguel, California
Cura Clinical Research
Palmdale, California
Integrative Skin Science and Research
Sacramento, California
University of California at Davis Medical Center
Sacramento, California
Allergy and Asthma Medical Group and Research Center
San Diego, California
University of California at San Diego Rady Childrens Hospital San Diego
San Diego, California
Clinical Science Institute
Santa Monica, California
Cura Clinical Research Sherman Oaks
Sherman Oaks, California
Velocity Clinical Research - Denver
Denver, Colorado
Childrens National Medical Center
Washington D.C., District of Columbia
Clinical Research of Brandon
Brandon, Florida
Academic Alliance in Dermatology - Saint Petersburg Office
Clearwater, Florida
Corazon United States of America, LLC doing business as Life Clinical Trials
Coral Springs, Florida
Palm Beach Dermatology Group
Delray Beach, Florida
Direct Helpers Research Center
Hialeah, Florida
Glick Skin Institute
Margate, Florida
Miami Clinical Research
Miami, Florida
ara Professionals Limited Liability Corporation
Miami, Florida
Deluxe Health Care LLC
Miami Lakes, Florida
Savin Medical Group LLC
Miami Lakes, Florida
Angels Clinical Research Institute
Miami Lakes, Florida
Optimal Research Sites, LLC
Orange City, Florida
Clinical Associates of Orlando Limited Liability Company
Orlando, Florida
Clinical Research Investments
Orlando, Florida
University of South Florida
Tampa, Florida
Centricity Research Columbus
Columbus, Georgia
Advanced Medical Research PC
Sandy Springs, Georgia
Divine Dermatology and Aesthetics
Savannah, Georgia
McIntosh Clinic PC
Thomasville, Georgia
Treasure Valley Medical Research
Boise, Idaho
Velocity Clinical Research - Boise
Meridian, Idaho
NorthShore University HealthSystem Clinical Trials Center
Skokie, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Showing 40 of 246 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.